In this Phase I clinical study, the investigators plan to offer investigational treatment
with the novel JAK2/STAT3 inhibitor WP1066 (Moleculin Biotech, Inc.) to pediatric patients
with any progressive or recurrent malignant brain tumor that is refractory to standard
treatment and is without known cure.
Phase:
Phase 1
Details
Lead Sponsor:
Emory University
Collaborators:
CURE Childhood Cancer, Inc. Peach Bowl LegACy Fund